|
WO2015192214A1
|
|
Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
|
|
AU2013293062A1
|
|
Anti-Siglec-15 antibodies
|
|
MD20140101A2
|
|
Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
|
|
BR112014020756A2
|
|
co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
|
|
CN102666585A
|
|
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
|
|
WO2011054112A1
|
|
Antibodies that specifically block the biological activity of kidney associated antigen 1
|
|
CA2816437A1
|
|
Antibodies that specifically block the biological activity of kidney associated antigen 1
|
|
CA2775793A1
|
|
Siglec 15 antibodies in treating bone loss-related disease
|
|
KR20110084280A
|
|
Antibodies that specifically block the biological activity of a tumor antigen
|
|
WO2009127059A1
|
|
Complexes of isogranulatimide and granulatimide with a cyclodextrm, formulations and their use for the treatment of cancer
|
|
WO2010066018A1
|
|
Novel human endogenous retorviral erv3 variant and uses thereof for diagnosing ovarian cancer
|
|
CA2826738A1
|
|
Polynucleotides and polypeptide sequences involved in cancer
|
|
CA2655933A1
|
|
Polynucleotides and polypeptide sequences involved in cancer
|
|
CA2822302A1
|
|
Methods of impairing osteoclast differentiation
|
|
CA2785046A1
|
|
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
|
EP2275547A2
|
|
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
